MSB 3.21% $1.13 mesoblast limited

t2d - very interesting...but, page-9

  1. 96 Posts.
    lightbulb Created with Sketch. 2
    The question I always ask with Phase 2 results is "If these results were replicated in a Phase 3 study would we obtain product approval?". The answer to this question for CHF and Disc repair is yes but the answer for t2d is no, not even close. In my original post I did concede that maybe a different approach may do the trick but you can bet that if Phase 2 had delivered a 0.7 reduction we would be looking down the barrel of another Phase 3 by now. I just don't think it's helpful to put an overly positive gloss on everything. It diminishes the real positives. I have to filter everything you and Vin say to look for the real substance.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.